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Abstract
Background: Nonencapsulated and nontypeable Haemophilus influenzae (NTHi) is a major cause of
human respiratory tract infections. Some strains of NTHi can cause invasive diseases such as septicemia
and meningitis, even if H. influenzae is not generally considered to be an intracellular pathogen. There have
been very few reports about the therapeutic efficacy of antibiotics against respiratory tract infection
caused by NTHi in mice because it is difficult for H. influenzae to infect mice. Therefore, we evaluated the
efficacy of antibiotics against NTHi in both a cell culture model and a mouse model of infection.
Methods: We used six strains of NTHi isolated from adult patients with chronic otitis media, namely
three β-lactamase-negative ampicillin (AMP)-resistant (BLNAR) strains and three β-lactamase-negative
AMP-susceptible (BLNAS) strains, to evaluate the efficacy of AMP, cefcapene (CFPN), levofloxacin (LVX),
clarithromycin (CLR), and azithromycin (AZM) in both a cell culture infection model and a mouse infection
model. In the cell culture infection model, strains that invade A549 human alveolar epithelial cells were
treated with each antibiotic (1 µg/ml). In the mouse infection model, female C57BL/6 mice were
intraperitoneally injected with cyclophosphamide (200 mg/kg) three days before intranasal infection with
1 × 109 colony-forming units (CFU) of NTHi and on the day of infection. After infection, the mice were
orally administered each antibiotic three times daily for three days, except for AZM, which was
administered once daily for three days, at a dose of 100 mg/kg/day.
Results: In the cell culture infection model, it was found that two BLNAR strains were able to enter the
cell monolayers by the process of macropinocytosis, and treatment with LVX yielded good bactericidal
activity against both strains inside the cells. In the mouse infection model, no bacteria were detected by
means of plating the lung homogenates of LVX-treated mice at day 4 after infection, while more than 105
CFU of bacteria per tissue sample were detected in nontreated mice.
Conclusion:  Our findings show the outcome and rich benefits of fluoroquinolone treatment of
respiratory infections caused by either invasive or noninvasive BLNAR strains of NTHi.
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Background
Haemophilus influenzae, a species that can cause systemic
disease in humans, is an obligate human commensal
found principally in the upper respiratory tract [1]. H.
influenzae can express one or none of six antigenically dis-
tinct polysaccharide capsules [1]. H. influenzae type b
(Hib) penetrates the nasopharyngeal mucosa of its host
by a presently unknown mechanism [2]. An in vitro inva-
sion assay showed that Hib has a very weak propensity to
enter cultured epithelial cells [2]. In contrast, a decapsu-
lated mutant of Hib was found to be consistently 20 to
100 times more invasive than its wild type [2]. Moreover,
nonencapsulated and nontypeable H. influenzae (NTHi)
are consistently over 1,000 times more invasive than Hib
[2]. Some strains of NTHi can cause invasive diseases such
as septicemia and meningitis, which suggests that the bac-
teria can pass through the cell layers and survive within
both epithelial and endothelial cells [3]. Actually, it has
been reported that NTHi can pass through viable cell lay-
ers of the human lung epithelial cell line NCI-H292 by
paracytosis, thus requiring bacterial protein synthesis,
even though the passage time is dependent on the growth
rate, which is influenced by the bacterial strains [4].
Although NTHi is a major cause of human infections at
present, to the best of our knowledge only one compara-
tive evaluation of antibiotics using an NTHi infection
model in mice has been reported [5]. As a matter of fact,
mouse models of infection are not typical for H. influenzae
because it is difficult for this bacterium to infect mice via
the respiratory route.
In the present study, we utilized the A549 human lung
epithelial cell line to characterize the invasive phenomena
of six clinically isolated strains of NTHi, namely three β-
lactamase-negative ampicillin (AMP)-resistant (BLNAR)
strains and three β-lactamase-negative AMP-susceptible
(BLNAS) strains. Two invasive strains were identified
among these six strains, and the invasive strains were then
used to evaluate the efficacy of antibiotics including AMP,
cefcapene (CFPN), levofloxacin (LVX), clarithromycin
(CLR), and azithromycin (AZM) in a cell culture model of
infection. In addition, the efficacy of each antibiotic was
also evaluated against each of the six isolated strains in an
established mouse model of chronic pulmonary infection
with the required chemically induced damage before
infection.
We show that LVX was the most effective antibiotic
against each NTHi strain across both cell culture and
mouse infection models.
Methods
Study design
This study was approved by the Ethics Committee on
Investigations of Experimental Pain in Conscious Ani-
mals, Kitasato Institute for Life Sciences, Kitasato Univer-
sity, which followed internationally recognized
guidelines.
Bacterial strains and culture conditions
We used six NTHi strains isolated in 2005 from adult
patients with otitis media in Japan (age range, 24–68
years; mean age, 40.5 years): three strains of BLNAR
(YS001, YS002, and YS005) for which the AMP minimum
inhibitory concentration (MIC) was ≥ 1.0 µg/ml, and
three strains of BLNAS (YS008, YS009, and YS010). Bacte-
ria were grown without shaking in brain heart infusion
(BHI) broth (Becton Dickinson and Company, Sparks,
MD, USA) supplemented with β-nicotinamide adenine
dinucleotide (β-NAD; 15 µg/ml) and hemin (15 µg/ml)
in 5% CO2 for 18 h at 37°C. A portion of this culture was
inoculated into fresh BHI broth supplemented with β-
NAD and hemin at a concentration of 10% (vol/vol). The
fresh culture was then incubated without shaking in 5%
CO2 for 3 h at 37°C before infection.
MIC
A routine agar dilution method was used to determine the
MIC of the antibiotics [6]. The test strains were inoculated
onto Muller-Hinton agar (Becton Dickinson and Com-
pany) supplemented with 0.5% yeast extract, 2% horse
lysate instead of β-NAD and hemin in 5% CO2 for 18 h at
37°C.
Cell culture model for H. influenzae infection
A549 cells (human lung carcinoma epithelial cell line,
American Type Culture Collection CCL-185; Manassas)
were cultured in Dulbecco's modified Eagle's medium
(DMEM; Sigma-Aldrich, St. Louis, MO, USA) containing
10%(vol/vol) heat-inactivated fetal calf serum, penicillin
(100 U/ml), and streptomycin (100 µg/ml). Cell cultures
were seeded at a density of 1 × 105 cells per well in 24-well
tissue culture plates with antibiotic-free culture medium
18 h prior to bacterial infection. The cell monolayers were
rinsed three times with Hanks' balanced salt solution
(HBSS; Sigma-Aldrich) to remove the antibiotics com-
pletely before bacterial infection.
For the invasion suppression assay of antibiotics, A549
cells were infected with NTHi at a multiplicity of infection
(MOI) of 100 bacteria per host cell in the presence or
absence (control) of 1 µg/ml of the antibiotic being tested
(AMP, AZM, CLR, CFPN, and LVX). A mild centrifugal
force (600 × g for 5 min) was applied to the 24-well tissue
culture plates at the start of the infection period. After
infection in 5% CO2 for 1 h at 37°C, the infected monol-
ayers were gently washed three times with 1 ml HBSS to
remove noninvasive bacteria, and incubated for 1 h in
fresh medium containing gentamicin (GEN; 100 µg/ml)
to kill the extracellular bacteria [2,7-9]. After incubationBMC Infectious Diseases 2008, 8:15 http://www.biomedcentral.com/1471-2334/8/15
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for 1 h, the monolayers were washed three times with
HBSS and lysed by vigorous aspiration with 1 ml phos-
phate buffered saline (PBS; pH 7.4) containing 0.1% (wt/
vol) sodium deoxycholate. The intracellular bacterial col-
ony-forming units (CFU) were enumerated by diluting
the lysed cells with PBS containing 0.01% (wt/vol) gelatin
(BSG) [10] and plating them on the BHI agar (Becton
Dickinson) supplemented with β-NAD and hemin using
triplicate sampling of each infected well.
For the intracellular killing assay of antibiotics, after a 1-h
treatment of GEN followed by a 1-h infection in the
absence of antibiotics, the monolayers were washed three
times with HBSS and were then further incubated with
fresh culture medium in the presence or absence (control)
of the antibiotic being tested in 5% CO2 for 2 h at 37°C.
After an additional 2 h of incubation, the monolayers
were washed three times with HBSS, and the intracellular
bacteria were harvested to enable enumeration of the bac-
terial CFU, as described above.
TEM
Infected cell monolayers on tissue culture inserts were
fixed with a fixative composed of 1% glutaraldehyde and
4% formaldehyde in a 0.06 M phosphate buffer (pH 7.4).
Samples were dehydrated in graded ethanol solutions,
and embedded in Epon 812 mixture (Ladd Research
Industries; Williston, VT, USA). Ultrathin sections were
made with a LKB ultramicrotome (Pharmacia LKB, Upp-
sala, Sweden), stained with aqueous uranyl acetate and
lead citrate, and analyzed with a JEOL 1200 EX-II trans-
mission electron microscope (TEM; JEOL Ltd., Tokyo,
Japan) at 80 kV as an accelerating voltage.
Mouse model for H. influenzae infection
Four-week-old female C57BL/6J (Slc11as,  H-2b) mice
(Charles River Japan, Yokohama, Japan) were injected
intraperitoneally with cyclophosphamide at three days
preinfection and on the day of infection at a dose of 200
mg/kg [11]. C57BL/6 mice were more susceptible than
BALB/c (Slc11as,  H-2d) mice to Psedomonas aeruginosa
infection in the agar-bead model [12]. The mice were
intranasally inoculated with 20 µl of the bacterial suspen-
sion in BSG (1 × 109 CFU/mouse). Each mouse received
intragastric administration of AMP, AZM, CLR, cefcapene
pivoxil (CFPN-PI), or LVX (100 mg/kg/day) suspended in
0.5% (wt/vol) methylcellulose (400 cP). All antibiotic
treatments except AZM were administered using a stom-
ach sonde attached to a 1-ml syringe three times daily,
while AZM was administered once daily for three days
after infection. Control mice received intragastric admin-
istration of 0.5% methylcellulose three times daily for
three days after infection. On day 4 after infection, the
lung was removed, homogenized with BSG, and plated in
order to determine the number of CFU [10,13-15].
Statistics
Significant differences between the means plus or minus
standard deviations (SDs) of different groups were exam-
ined using a two-tailed unpaired Student's t test. A P value
of < 0.05 was regarded as statistically significant.
Results
In vitro susceptibility testing
The MICs of AMP, AZM, CLR, CFPN, LVX, and GEN
against the six strains of NTHi are shown in Table 1. The
MIC ranges of the antibiotics tested against the three
BLNAR and the three BLNAS strains were as follows:
BLNAR, AMP 1–4 mg/l; AZM 0.25–8 mg/l; CLR ≥ 8 mg/l;
CFPN 1 mg/l; LVX ≤ 0.125 mg/l; and GEN 4 mg/l; BLNAS,
AMP 0.25–0.5 mg/l; AZM 4–8 mg/l; CLR 8–16 mg/l;
CFPN 0.063–0.125 mg/l; LVX ≤ 0.125 mg/l; and GEN 2–
4 mg/l. It was clearly shown that LVX has high in vitro
potency against both the BLNAR and BLNAS strains. Both
AMP and CFPN also showed high potency against the
BLNAS strains.
Extracellular potency of antibiotics against H. influenzae 
entry into A549 cells
We first examined the entry level of NTHi strains into
A549 cells using a GEN protection assay. Although there
was somewhat less variability in invasiveness among
strains, two (YS001 and YS005) of the six tested strains
were considered to be invasive strains (Fig. 1). It was
reported previously in TEM analyses and confocal macro-
scopic studies that NTHi can initiate cytoskeletal rear-
Table 1: In vitro potency of six antimicrobial agents against six clinical isolates of NTHi.
strain MIC (µg/ml) BLNAR or BLNAS
AMP AZM CLR CFPN LVX GEN
YS001 4 8 >16 1 ≤0.125 4 BLNAR
YS002 4 0.25 8 1 ≤0.125 4 BLNAR
YS005 1 8 16 1 ≤0.125 4 BLNAR
YS008 0.25 4 8 0.125 ≤0.125 4 BLNAS
YS009 0.5 4 16 0.125 ≤0.125 2 BLNAS
YS010 0.25 8 16 0.063 ≤0.125 4 BLNASBMC Infectious Diseases 2008, 8:15 http://www.biomedcentral.com/1471-2334/8/15
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rangement within the human airway epithelium, resulting
in the internalization of the bacteria within nonciliated
human airway epithelial cells by the process of macropi-
nocytosis [16]. Using TEM analysis, we detected the
microvilli of A549 cells surrounding organisms, as shown
in Fig. 2. Therefore, we assume that some but not all NTHi
strains are able to enter epithelial cells by the process of
macropinocytosis. We next examined the inhibitory
effects of each antibiotic on the entry and replication of
YS001 and YS005 in A549 cells. The cells were infected
with either YS001 or YS005 (MOI = 100) for 1 h at 37°C
in the cell culture medium supplemented with each anti-
biotic (AMP, AZM, CLR, CFPN, or LVX; 1 µg/ml) or in cell
culture medium that was not supplemented. Figure 3
shows that the LVX treatment was the most effective of the
antibiotics tested in the present study in suppressing the
entry of every strain into this line of cells. AMP or AZM
treatment decreased the number of intracellular bacteria
of each strain by 70–85%, while CLR or CFPN treatment
decreased the number of bacteria by 30–50%. These
results indicate that the ranking of the treatments in terms
of their efficacy for suppressing the entry of invasive
BLNAR strains was LVX>AMP = AZM>CLR = CFPN.
Intracellular potency of antibiotics against H. influenzae 
within A549 cells
After infection with YS001 or YS005 for 1 h at 37°C in the
cell culture medium without supplementation of any
antibiotic followed by subsequent incubation for 1 h in
fresh medium supplemented with GEN to kill extracellu-
lar bacteria, the infected monolayers were further incu-
bated with fresh culture medium supplemented with each
antibiotic (AMP, AZM, CLR, CFPN, or LVX; 1 µg/ml) or
not supplemented for 2 h at 37°C. Figure 4 shows that the
LVX treatment was the most effective in reducing the
number of intracellular bacteria of every strain. In con-
trast, intracellular bactericidal activities brought about by
treatment with the other four antibiotics were detected in
each strain, but to different degrees. The intracellular bac-
tericidal activity against invasive BLNAR strains of the
tested antibiotics can be ranked as follows:
LVX>AZM>AMP = CLR = CFPN.
Mouse model of intranasal infection with H. influenzae
To date, mouse models of H. influenzae pneumonia have
been rarely reported since it is difficult for this bacterium
to infect mice [17,18]. Therefore, we pursued a new
mouse model of NTHi lung infection in order to evaluate
the efficacy of the antibiotics tested. In the present study,
we used 4-week-old C57BL/6 mice. Generally, young
immature mice are more susceptible to bacterial infection
than fully grown mice [19]. In addition, the mice were
pretreated intraperitoneally with cyclophosphamide to
induce granulocytopenia [20]. We previously observed a
decrease of at least 90% in peripheral blood granulocytes
after cyclophosphamide treatment [11]. When cyclophos-
Electric microscopic observation of A549 cells infected with  YS001 Figure 2
Electric microscopic observation of A549 cells infected with 
YS001. Bacteria attached (arrows) to the cell and the micro-
villi (arrow heads) of the cell are recognized. Bars, 1 µm (A) 
and 0.5 µm (B).
Entry of H. influenzae into A549 cells Figure 1
Entry of H. influenzae into A549 cells. Cell cultures (1 × 105 
cells/well) were infected for 1 h at 37°C with 1 × 107 CFU of 
YS001, YS002, YS005, YS008, YS009, or YS010. At 1 h after 
infection, the cell culture medium was exchanged for fresh 
medium containing GEN (100 µg/ml). One hour later, the 
surviving intracellular bacteria were enumerated by plating. 
Data represent the means ± SD of three experiments with 
triplicate assays. ND, not detected.
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phamide-pretreated mice were intranasally inoculated
with 1 × 109 CFU of NTHi, the bacteria continuously
resided in the lungs of the mice at more than 105 CFU
when monitored for up to four days after inoculation
(data not shown).
Efficacies of antibiotics against H. influenzae colonization 
in mouse lung
We evaluated the efficacy of the antibiotics for reducing
the colonization of NTHi in the mouse lung. Based on the
data from previous reports [21-24] and the suppliers'
instructions, we estimated peak antibiotic concentrations
of 1 to 2 µg/ml (AZM and CFPN-PI), 2 to 3 µg/ml (AMP
and LVX), or 5 to 6 µg/ml (CLR) in the blood of mice from
30 to 120 min after intragastric administration. Figure 5
shows that the intragastric administration of LVX was
extremely effective against both the BLNAR and BLNAS
strains of NTHi. The AZM treatment was also extremely
effective for the complete eradication of BLNAS strains
from the lung, while the CLR treatment showed no effi-
cacy. Treatment with AMP or CFPN-PI was also highly
effective against BLNAS infection. However, except for
LVX, none of the tested antibiotics was found to be effec-
tive against invasive BLNAR strains.
Discussion
NTHi strains are not traditionally considered to be inva-
sive [1,25]; however, recent works have shown that NTHi
can penetrate human respiratory epithelial cell lines [4,7]
and primary human airway epithelial cells [16]. In addi-
Intracellular killing assay of antibiotics Figure 4
Intracellular killing assay of antibiotics. A549 cells (1 × 105 
cells/well) were infected for 1 h at 37°C with 1 × 107 CFU of 
YS001 (A) or YS005 (B) in the absence of antibiotics. After a 
1-h infection followed by a 1-h incubation period with GEN 
(100 µg/ml), the cell culture was incubated in the presence or 
absence (control) of AMP, AZM, CLR, CFPN, or LVX (1 µg/
ml). Two hours later, the surviving intracellular bacteria were 
enumerated by plating. Data represent the means ± SD of 
three experiments with triplicate assays. *, P < 0.05 (com-
pared with control). **, P < 0.01 (compared with control). 
ND, not detected.
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The invasion suppression assay of antibiotics Figure 3
The invasion suppression assay of antibiotics. A549 cells (1 × 
105 cells/well) were infected for 1 h at 37°C with 1 × 107 
CFU of YS001 (A) or YS005 (B) in the presence or absence 
(control) of AMP, AZM, CLR, CFPN, or LVX (1 µg/ml). At 1 
h after infection, the cell culture medium was exchanged for 
fresh medium containing GEN (100 µg/ml). One hour later, 
surviving intracellular bacteria were enumerated by plating. 
Data represent the means ± SD of three experiments with 
triplicate assays. *, P < 0.05 (compared with control). ND, 
not detected.
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tion, some reports have shown that NTHi can reside intra-
cellularly in human tissue samples [3,9,26]. In the present
study, two of the three BLNAR strains examined certainly
entered the A549 human lung epithelial cell line (Fig. 1).
Nevertheless, in the mouse infection model, there were no
differences in the infection doses of bacteria in the lung
homogenates between BLNAR and BLNAS or between
invasive and noninvasive strains (Fig. 5). To date, we have
been unable to detect intracellular bacteria in lung sec-
tions by TEM analysis after infection with NTHi.
LVX showed potent in vitro antibacterial activity against
both the BLNAR and BLNAS strains (Table 1), and was
found to be overwhelmingly effective against invasive
BLNAR strains in the cell culture infection model (Figs. 3
and 4). After 1-h incubation in 5% CO2 at 37°C, LVX used
at a concentration of 1 µg/ml (≥ 8 times the MIC) killed
about 99% of bacteria (both YS001 and YS005) in the cell
culture medium; still, as many as 1 × 105 CFU per well of
extracellular bacteria were present after the LVX treatment
(data not shown). The 1 × 105 CFU of live bacteria was
surplus to the amount required for entering the cells, since
YS001 and YS005 were able to enter the cells with 1.3 ×
103 CFU and 2.4 × 102 CFU, respectively (Fig. 2). Conse-
quently, LVX appears to have an extracellular potency to
suppress the invasion of bacteria, since almost no bacte-
rium was detected within the cells after the LVX treatment
(Fig. 3). By comparison, it seems that AMP, AZM, or CLR
used at lower concentrations of 1/4, 1/8, or 1/16 of MIC,
respectively, all have extracellular potency to suppress the
invasion of BLNAR strains into A549 cells, as shown in
Fig. 3. We have previously reported that a sub-MIC of
AZM can reduce the invasive activity of Salmonella enterica
serovar Typhimurium into the Henle-407 human intesti-
nal epithelial cell line [10]. Presumably, then, a sub-MIC
of each antibiotic might affect the expression of the bacte-
rial invasion apparatus directly and/or indirectly. Fluoro-
quinolones have long been known to accumulate in
eukaryotic cells. The cellular concentrations of fluoroqui-
nolones are generally 4- to 10-fold higher than the extra-
cellular concentrations [27]. In contrast, up to now, all
studies have reported a lack of accumulation (i.e., an
Bacterial clearance by antibiotic treatment in the lung Figure 5
Bacterial clearance by antibiotic treatment in the lung. Mice infected intranasally with YS001, YS002, YS005, YS008, YS009, or 
YS010 were intragastically administered AMP, AZM, CLR, CFPN-PI, LVX (100 mg/kg/day), or methylcellulose (control) once 
(AZM) or three times (AMP, CLR, CFPN-PI, LVX, and methylcellulose) daily for three days after infection. On day 4 after infec-
tion, the mice were harvested, and bacterial loads were determined in lung homogenates. Data represent the means ± SD of 
five mice per group. *, P < 0.05 (compared with control). **, P < 0.01 (compared with control). ND, not detected.
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apparent intracellular concentration lower than the extra-
cellular concentration at equilibrium) for all β-lactams
[27].
In sharp contrast with β-lactams, macrolides show a
marked intracellular accumulation in almost all cells. The
cellular concentrations of CLR and AZM are 10- to 20-fold
and 40- to 300-fold larger, respectively, than the extracel-
lular concentrations [27]. Still, it seems that every antibi-
otic can reduce the intracellular CFU of invasive BLNAR
strains to some extent, as shown in Fig. 4. Accordingly,
intracellular bacteria are exposed to various killing actions
of the cells. Most obligate and facultative intracellular bac-
teria have mechanisms for escaping from the killing sys-
tems inside the cells. In contrast to such bacteria, the
response of NTHi to the defense system inside the cells
remains unclear; however, intracellular NTHi must suffer
a synergy effect between the activity of the antibiotic and
the killing actions of the cells. Moreover, we must also
consider the fact that antibiotics may exert either favora-
ble or unfavorable action on the host cells, which in turn
modulate the bactericidal activity of the antibiotics [27].
H. influenzae is a strict parasite of humans which effi-
ciently colonizes the upper respiratory tract [1]. When
constructing the mouse model of intranasal infection with
NTHi, we considered using the ICR, ddY, and C57BL/6
mouse strains. As a result of the preliminary experiments,
intranasally inoculated bacteria were detected in the lungs
of cyclophosphamide-pretreated C57BL/6 mice, while the
inoculated bacteria were not detected in the lungs of
cyclophosphamide-pretreated ICR or ddY mice. On the
one hand, C57BL/6 mice carry the Nramp1D169 (natural
resistance-associated macrophage protein 1 gene; new
nomenclature, Slc11a1) allele (a point mutation at nucle-
otide position 596, resulting in a glycine-to-aspartate sub-
stitution) in the genetic background. On the other hand,
ICR and ddY mice carry the Nramp1G169 gene. A single
locus (Nramp1) that is mapped to the proximal region of
mouse chromosome 1 has been shown to influence the
early phase of bacterial replication in reticuloendothelial
cells [28]. The expression of Nramp1  in mice confers
innate resistance to certain bacterial infections such as
Mycobacterium bovis (BCG), Leishmania donovani, and S.
enterica serovar Typhimurium [29,30]. Therefore, C57BL/
6 mice are susceptible to infection with these bacteria. It is
possible that the expression of Nramp1 in mice would also
confer innate immunity to infection with H. influenzae, so
NTHi could colonize in the lungs of C57BL/6 mice after
intranasal infection.
It has been reported that in Japanese and U.S. clinical iso-
lates, the prevalence rates of each resistance class of H.
influenzae in Japan (n = 296) and the United States (n =
100) are, respectively, 55.1% and 46% for BLNAS; 26.4%
and 13% for low-BLNAR with a low degree of AMP resist-
ance; 13.2% and 0% for BLNAR; 3% and 36% for TEM-1
type and ROB-1 type β-lactamase-producing AMP-resist-
ant  H. influenzae (BLPAR); and 2.4% and 3% for Hib
strains [31]. These data indicate a worldwide increase of
AMP-resistant H. influenzae isolates. Therefore, it seems
likely that the use of fluoroquinolones or macrolides for
the oral treatment of respiratory tract infections associated
with H. influenzae should be useful. In fact, fluoroqui-
nolones have been widely used in the treatment of respi-
ratory tract infections, and their use has increased
extensively in hospitals and long-term care facilities [32].
However, it has also been reported that the emergence of
H. influenzae isolates with reduced susceptibility to fluor-
oquinolones is becoming a clinical and public health con-
cern [33-35]. Under these circumstances, the new
guidelines in the context of the risk management of com-
munity-acquired pneumonia in adults are the following:
Young and otherwise healthy patients who can be safely
treated as outpatients will usually respond to AZM. Doxy-
cycline should be used with caution because of increasing
resistance to this agent, and reserved for use when other
options are not available. Older patients, or those with
substantial comorbidities, will usually respond well to
combinations of a β-lactam agent (such as high-dose
amoxicillin/clavulanate) plus a macrolide. Newer genera-
tion recommended (so-called "respiratory") fluoroqui-
nolones can be used as first-line agents but should be
reserved for use in higher risk or drug-intolerant patients
in order to slow the emergence of resistance to this class of
drugs [36]. Therefore, in spite of the fact that the oral LVX
treatment showed excellent therapeutic efficacy in the
mouse model of intranasal infection with NTHi com-
pared with other antibiotic treatments (Fig. 5), fluoroqui-
nolones should be avoided or used with great caution. As
another option, combinations of a β-lactam agent plus a
macrolide could be expected to have a modest therapeutic
benefit in the oral treatment of respiratory tract infections
associated with H. influenzae, which we will examine in
future studies.
Miyazaki et al. have demonstrated that although the MICs
of AZM and CLR are similar for three strains of H. influen-
zae (BLNAR, BLNAS, and BLPAR) at a dose of 50 mg/kg,
the area under the concentration curve and the half-life of
AZM in the lungs are 3-fold higher and 6-fold longer,
respectively, than those of CLR in mice. Thus, the authors
concluded that AZM may be useful for both AMP-suscep-
tible and AMP-resistant bronchopneumonia caused by H.
influenzae infections [5]. The present results support their
conclusion. AZM has potent antibacterial activity against
BLNAS strains in mice compared with CLR (Fig. 5). It is
well known that since AZM, the only azalide macrolide
antibiotic, has the advantage of an extensive half-life of
approximately 68 h, it is possible to administer it once aBMC Infectious Diseases 2008, 8:15 http://www.biomedcentral.com/1471-2334/8/15
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day for a short duration while sustaining effective serum
and tissue concentrations for at least 10 days [37]. The
intracellular (i.e., within leukocytes and fibroblasts) and
tissue concentrations of AZM make it an excellent option
for intracellular pathogens [37]. The dose and frequency
of the oral administration of each antibiotic used in the
present study in the treatment of a 70 kg adult human as
recommended by the suppliers are as follows: AMP, 250–
500 mg, four to six times daily; AZM, 500 mg once daily;
CLR, 200 mg, twice daily; CFPN-PI, 100 mg, three times
daily; and LVX, 100 mg, three times daily. Therefore, the
dose for the oral administration of each antibiotic in mice
in the present study was set at 100 mg/kg daily, which is
thought to be two to 23 times more than sufficient to pro-
duce effective antibacterial activity. Nevertheless, with the
exception of LVX, we found no antibiotics that were effec-
tive against invasive BLNAR strains (YS001 and YS005) in
the mouse infection model (Fig. 5). We hope that our
future studies on invasive BLNAR strains using the mouse
infection model will identify effective antibiotics for
human medical use.
Conclusion
In summary, fluoroquinolone LVX had potent activities
against both the process of invasion into the A549 human
lung epithelial cell line and the residence in the cell line of
invasive BLNAR strains of NTHi, as compared with AMP,
AZM, CLR, and CFPN. For the mouse model of infection
with NTHi, four-week-old female C57BL/6 mice were pre-
treated intraperitoneally with cyclophosphamide to
induce granulocytopenia before intranasal infection with
NTHi. We evaluated the efficacy of the antibiotics at
reducing the colonization of NTHi in the mouse lung. The
results showed that LVX was extremely effective in treating
both the BLNAR and BLNAS strains of NTHi as compared
with AMP, AZM, CLR, and CFPN-PI. In particular, with
the exception of LVX, there were no antibiotics that were
effective against invasive BLNAR strains in the mouse
infection model. These observations provide evidence
that fluoroquinolones have great bactericidal activities
against quinolone-susceptible NTHi strains. Further stud-
ies are needed to identify effective antibiotics for human
use other than fluoroquinolones as an initial treatment
that provides coverage of both BLNAR and BLNAS or inva-
sive and noninvasive strains of NTHi.
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